**FORM A ACCEPTANCE**

**Basic**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Scandia number: |  | | Person number: |  |
|  |  | |  |  |
| Surname: |  | | First name: |  |
|  |  | |  |  |
| Weight: \_\_\_\_\_\_\_ | kg | | Height: \_\_\_\_\_\_\_ | cm |
|  |  | |  | |
| Diabetes: | \_\_\_\_\_ | (1: Type 1/ 2: Type 2/ 3: Type 1+2/ N: No/ NA: NA/ U: Unclassified) | | |
|  |  | |  | |

***Events (at any time up to acceptance):***

|  |  |  |
| --- | --- | --- |
| Encephalopathy | \_\_\_\_\_ | (1: Grade 1/ 2: Grade 2/ 3: Grade/ 4: Grade 4/ 5: Yes, grade unknown/ N: No/ ND: Unknown) |
| Variceal bleeding | \_\_\_\_\_ | (N: No/ ND: Unknown/Y: Yes) |
| Ascites | \_\_\_\_\_ | (0: None/1: Controlled w. Medication/2: Refractory) |

***Events at acceptance on waiting list (within +/- 2 weeks):***

|  |  |  |
| --- | --- | --- |
| In hospital  (except control) | \_\_\_\_\_ | (N: No/ ND: Unknown/Y: Yes) |
| Ventilator | \_\_\_\_\_ | (N: No/ ND: Unknown/Y: Yes) |

**Previous malignancy**

|  |  |  |
| --- | --- | --- |
| Type | \_\_\_\_\_ | (LPD: Lymphoproliferative/ LT: Liver tumor/ ND: Unknown/ None: None/ OT: Other) |
| Year | \_\_\_\_\_ |  |
| Comments | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | |

**Diagnosis (see lists)**

|  |  |
| --- | --- |
| Primary diagnosis | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| Secondary diagnosis | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
|  | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| Re-transpl. diagnosis | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |

**FORM A cont.**

***At acceptance on waiting list (within +/- 2 weeks for non-acute patients, within a few days for acute patients)***

**Laboratory test**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Hemoglobin | \_\_\_\_\_\_\_\_\_\_\_ | mmol/l | ­\_\_\_\_\_\_\_\_\_\_\_ | g/l |
| Thrombocytes | \_\_\_\_\_\_\_\_\_\_\_ | 109/l |  |  |
| Na (Sodium) | \_\_\_\_\_\_\_\_\_\_\_ | mmol/l |  |  |
| INR | \_\_\_\_\_\_\_\_\_\_\_ |  |  |  |
| ASAT | \_\_\_\_\_\_\_\_\_\_\_ | μkat/l | \_\_\_\_\_\_\_\_\_\_\_ | U/l |
| ALAT | \_\_\_\_\_\_\_\_\_\_\_ | μkat/l | \_\_\_\_\_\_\_\_\_\_\_ | U/l |
| Albumin | \_\_\_\_\_\_\_\_\_\_\_ | μmol/l | \_\_\_\_\_\_\_\_\_\_\_ | g/l |
| Bilirubin | \_\_\_\_\_\_\_\_\_\_\_ | μmol/l |  |  |
| Creatinine | \_\_\_\_\_\_\_\_\_\_\_ | μmol/l |  |  |
| Urea in plasma | \_\_\_\_\_\_\_\_\_\_\_ | mmol/l |  |  |
| GFR | \_\_\_\_\_\_\_\_\_\_\_ | ml/min 1,73m2 |  |  |
| GFR method | \_\_\_\_\_\_\_\_\_\_\_ | (CA: Calculated, estimated/ME: Measured) | | |

|  |  |  |
| --- | --- | --- |
| Dialysis | \_\_\_\_\_ | (N: No/ ND: Unknown/Y: Yes) |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Alfa-1-foetoprotein | \_\_\_\_\_\_\_\_\_\_\_ | μ/L | (if below 5, state 0) | |
| CA19-9 | \_\_\_\_\_\_\_\_\_\_\_ | U/mL |  |  |
| CEA | \_\_\_\_\_\_\_\_\_\_\_ | ng/ml |  |  |

**FORM A cont.**

**Virology & bacteriology**

|  |  |  |
| --- | --- | --- |
| Anti-CMV | \_\_\_\_\_ | -: Negative/ ND: Not done/ +: Positive |
| Anti-SARS-CoV-2 (Covid-19 antibody) | \_\_\_\_\_ | -: Negative/ ND: Not done/ +: Positive |
| SARS-CoV-2 RNA (Covid-19) | \_\_\_\_\_ | -: Negative/ ND: Not done/ +: Positive |
| Anti-EBV IgG | \_\_\_\_\_ | -: Negative/ ND: Not done/ +: Positive |
| Anti-HBc | \_\_\_\_\_ | -: Negative/ ND: Not done/ +: Positive |
| Anti-HBs | \_\_\_\_\_ | -: Negative/ ND: Not done/ +: Positive |
| Hepatitis Bs antigen | \_\_\_\_\_ | -: Negative/ ND: Not done/ +: Positive |
| Anti-HCV | \_\_\_\_\_ | -: Negative/ ND: Not done/ +: Positive |
| Hepatitis C antigen | \_\_\_\_\_ | -: Negative/ ND: Not done/ +: Positive |
| Hepatitis Delta Virus | \_\_\_\_\_ | -: Negative/ ND: Not done/ +: Positive |
| Anti-HIV | \_\_\_\_\_ | -: Negative/ ND: Not done/ +: Positive |
| HIV antigen | \_\_\_\_\_ | -: Negative/ ND: Not done/ +: Positive |
| Anti-HSV | \_\_\_\_\_ | -: Negative/ ND: Not done/ +: Positive |
| Syphilis antibody | \_\_\_\_\_ | -: Negative/ ND: Not done/ +: Positive |
| Anti-MV IgG | \_\_\_\_\_ | -: Negative/ ND: Not done/ +: Positive |
| Toxoplasma antibodies | \_\_\_\_\_ | -: Negative/ ND: Not done/ +: Positive |
| Varicella zoster virus | \_\_\_\_\_ | -: Negative/ ND: Not done/ +: Positive |

|  |  |
| --- | --- |
| Hep C genotypes | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |

**FORM B cont.**

**Basic**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Scandia number: |  | | | Person number: | |  |
|  |  | | |  | |  |
| Surname: |  | | | First name: | |  |
| Tx date/initial reperfusion(porta or artery) |  | | |  | |  |
| Date: \_\_\_\_\_\_\_\_\_\_ | | | Time: | \_\_\_\_\_\_\_ |  |
|  |  | | |  |  |  |
| Weight: | \_\_\_\_\_kg | | | Height: | \_\_\_\_\_\_\_ | cm |
|  |  | | |  | |  |
| Encephalopathy | | \_\_\_\_\_ | (1: Grade 1/ 2: Grade 2/ 3: Grade/ 4: Grade 4/ 5: Yes, grade unknown/ N: No/ ND: Unknown) | | | |
| Ascites | | \_\_\_\_\_ | (0: None/1: Controlled w. Medication/2: Refractory/ND: Not done) | | | |
| Artificial liver support | | \_\_\_\_\_ | (M: Mars/ N: No/P: Prometheus) | | | |
| No. of treatments | | \_\_\_\_\_ |  | | | |
| Ventilator | | \_\_\_\_\_ | (N: No/ ND: Unknown/Y: Yes) | | | |
| Medical care status (UNOS) | | \_\_\_\_\_ | (1: Intensive care unit-bound/ 2: Cont. hospitalization/ 3: Cont. medical care/ 4: At home with normal function/ 5: Not done/unknown) | | | |

**Laboratory test (obligatory for (i)MELD calculation)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Hemoglobin | \_\_\_\_\_\_\_\_\_\_\_ | mmol/l | ­\_\_\_\_\_\_\_\_\_\_\_ | g/lg/100ml |
| Thrombocytes | \_\_\_\_\_\_\_\_\_\_\_ | 109/l |  |  |
| INR | \_\_\_\_\_\_\_\_\_\_\_ |  |  |  |
| ASAT | \_\_\_\_\_\_\_\_\_\_\_ | μkat/l | \_\_\_\_\_\_\_\_\_\_\_ | U/l |
| ALAT | \_\_\_\_\_\_\_\_\_\_\_ | μkat/l | \_\_\_\_\_\_\_\_\_\_\_ | U/l |
| Albumin | \_\_\_\_\_\_\_\_\_\_\_ | μmol/l | \_\_\_\_\_\_\_\_\_\_\_ | g/l |
| Na (Sodium) | \_\_\_\_\_\_\_\_\_\_\_ | mmol/l |  |  |
| Bilirubin | \_\_\_\_\_\_\_\_\_\_\_ | μmol/l |  |  |
| Creatinine | \_\_\_\_\_\_\_\_\_\_\_ | μmol/l |  |  |
| Urea in plasma | \_\_\_\_\_\_\_\_\_\_\_ | mmol/l |  |  |

**FORM B cont.**

|  |  |  |
| --- | --- | --- |
| Dialysis | \_\_\_\_\_ | (N: No/ ND: Unknown/Y: Yes) |

**Pre & post pathology**

***Liver pre-pathology:***

|  |  |  |
| --- | --- | --- |
| Liver tumor diagnosed | \_\_\_\_\_ | (1: Before LT/ 2: After LT (at pathology)/ 3: No) |
| Cumulative pre-LT treatment | \_\_\_\_\_ | (NO: None/ CE: Chemoembolization (TACE)/ RE: Resection/ RF: Radiofrequency/ AL: Alcohol/ CR: Cryotherapy/ RT: Radiotherapy/ SO: Sorafenib/ RZ: Radioembolization/ OT: Other) |

***Liver post-pathology:***

|  |  |  |
| --- | --- | --- |
| Non tumoral status | \_\_\_\_\_ | (1: Cirrhosis (Metavir F4)/ 2: Fibrosis (Metavir F1-F3)/ 3: Normal (Metavir F0)) |
| Malign liver tumor diagnosed | \_\_\_\_\_ | (N: No/ ND: Unknown/Y: Yes) |
| Liver tumor type | \_\_\_\_\_ | (CC: Cholangio carcinoma/ HCC: Hepatocellular carcinoma/ OT: Other) |
| Portal Tumoral thrombosis | \_\_\_\_\_ | (N: No/ ND: Unknown/Y: Yes) |
| Liver tumor comments | **­­­­­­­**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | |
| Liver tumor number | \_\_\_\_\_ |  |
| Liver tumor diameter (largest) | \_\_\_\_\_ | mm |
| Extraheptic growth | \_\_\_\_\_ | (N: No/ ND: Unknown/Y: Yes) |
| Vascular invasion | \_\_\_\_\_ | (0: No/ 1: Macro/ 2: Micro) |

**Operation**

|  |  |  |
| --- | --- | --- |
| Graft weight | \_\_\_\_\_ | g |
| Macrovesicular steatosis | \_\_\_\_\_ | (1: none/ 2: mild/ 3: moderate (30%-60%)/ 4: severe (>60%)/ N: N/A) |
| Microvesic steatosis | \_\_\_\_\_ | (1: none/ 2: mild/ 3: moderate (30%-60%)/ 4: severe (>60%)/ N: N/A) |
| Overall steatosis | \_\_\_\_\_ | (1: none/ 2: mild/ 3: moderate (30%-60%)/ 4: severe (>60%)/ N: N/A) |
|  |  |  |
| Assessment of steatosis: | \_\_\_\_\_ | (V: Visual/ B: Biopsy/ O: Other/ U: Unknown) |
| Fibrosis: | \_\_\_\_\_ | (F0: no fibrosis/ F1: Portal, without septa/ F2: Portal, with few septa/ F3: Numerous septa without cirrhosis/ F4: Cirrhosis) |

|  |  |  |
| --- | --- | --- |
| Complete reperfusion (porta and artery) |  | Date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Time: \_\_\_\_\_ |
| Cold ischemia time (DBD/DCD) | \_\_\_\_\_ | hours \_\_\_\_\_ minutes |
| Functional warm ischemia time (DCD) | \_\_\_\_\_ | hours \_\_\_\_\_ minutes |
| Biliary anastomosis | \_\_\_\_\_ | (CC: Chol-cholstomy/ CD: Chol-Duod/ CJ: Chol-jejenostomy/ ND: Not Done / unknown) |
| By pass | \_\_\_\_\_ | (1: Extracorporeal by pass/ 2: Lateral clamping of the vena cava /3: Neither EC nor VCP/ 4: No/ 5: Unknown) |
| Arterial reconstruction | \_\_\_\_\_ | (N: None/ D: Donor/ R: Recipient/ NA: Not available) |
| Cava reconstruction | \_\_\_\_\_ | (C: Conventionel/ S: Side-to-side cavaplasty/ P: Piggy-back/O: Other/ NA: Not available) |

**FORM B cont.**

***Immunosuppression (during first month)***

|  |  |
| --- | --- |
| ALG: Anti-lymphocyte globulin | **□** |
| ASA: Acetic salicylic acid | **□** |
| ATG: Anti-thymocyte globulin | **□** |
| AZA: Azathioprin | **□** |
| AZM: Azitomycin | **□** |
| BAS: Basiliximab | **□** |
| BLI: Blinded drug | **□** |
| CB: calcium channel blocker | **□** |
| CSA: Cyclosporin-A | **□** |
| DAC: Daclizumab | **□** |
| EVE: Everolimus | **□** |
| FK: Tacrolimus | **□** |
| FOT: Fotopheres | **□** |
| GAM: Gammaglobolin | **□** |
| GLU: Glucocorticosteroids | **□** |
| IL2: IL-2 block | **□** |
| MFA: Mycophenolate acid | **□** |
| MMF: Mycomophetil | **□** |
| NON: None | **□** |
| OKT: Anti-CD3 antibodies | **□** |
| OTH: Other | **□** |
| PLA: Plasmapheres | **□** |
| RAP: Rapamycin | **□** |
| SIR: Sirolimus | **□** |
| STA: Statins | **□** |
| TLI:TLI | **□** |

**FORM B cont.**

**Early post-op. information**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Lab. results within 15 days after tx: | | | | |
| Max bilirubin | \_\_\_\_\_\_\_\_\_\_\_ | μmol/l | \_\_\_\_\_\_\_\_\_\_\_ | mg/dl |
| Max INR | \_\_\_\_\_\_\_\_\_\_\_ |  |  |  |
| Max creatinine | \_\_\_\_\_\_\_\_\_\_\_ | μmol/l |  |  |
|  |  |  |  |  |
| Early complications within 1 month after tx \_\_\_\_\_\_\_\_\_\_\_ (N: No/ NE: Not examined/Y: Yes)   |  |  |  |  | | --- | --- | --- | --- | | Early complication |  |  | Treatment | | AB: Abscess | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | | AL: Anastomosis leakage | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | | AT: Arterial thrombosis | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | | BF: Biliary fistula | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | | BL: Bleeding | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | | BS: Biliary collection | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | | CA: Cardiac | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | | CE: Cerebral | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | | GA: Gastro | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | | GR: Graft Related | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | | IC: Infected collection | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | | IF: Infection (not wound) | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | | LI: Liver insufficiency | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | | NC: Non-infected collection | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | | NO: No major complication | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | | OT: Others | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | | PE: Pulmonary embolism | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | | PF: pleural effusion | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | | PH: Phlebitis | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | | PT: Portal thrombosis | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | | RE: Respiratory | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | | RJ: Rejection | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | | RR: Reduced Renal Function | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | | SS: Small for size | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | | SY: Systemic | □ | \_\_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | |  |  |  |  | | WI: Wound infection | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | | WR: Wound related (not infection) | □ | \_\_\_\_\_ | (1: medical/ 2: interventional drainage/3: reop./ 4: other) | |  |  |  |  | | | | | |

**FORM C** **FOLLOW-UP**

***(Minimum use: 1, 3, 5, 10, 15, 20, 25, 30 years controls)***

**Basic**

|  |  |  |  |
| --- | --- | --- | --- |
| Scandia number: | ­\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | Person number: | ­\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
|  |  |  |  |
| Surname: | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | First name: | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
|  |  |  |  |
| Weight: \_\_\_\_\_\_\_ | kg | Height: \_\_\_\_\_\_\_ | cm |
| Follow-up date: | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |  |  |

**Laboratory test**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| INR | \_\_\_\_\_\_\_\_\_\_\_ |  |  |  |
| Albumin | \_\_\_\_\_\_\_\_\_\_\_ | μmol/l | \_\_\_\_\_\_\_\_\_\_\_ | g/l |
| Bilirubin | \_\_\_\_\_\_\_\_\_\_\_ | μmol/l |  |  |
| Creatinine | \_\_\_\_\_\_\_\_\_\_\_ | μmol/l |  |  |
| GFR | \_\_\_\_\_\_\_\_\_\_\_ | ml/min 1,73m2 |  |  |
| GFR Method | \_\_\_\_\_\_\_\_\_\_\_ | (CA: Calculated / ME: Measured) | | |
| Dialysis | \_\_\_\_\_\_\_\_\_\_\_ | (N: No/ ND: Unknown/Y: Yes) | | |

**FORM C** **FOLLOW-UP cont.**

**Immunosuppression**

***Current Immunosuppression***

|  |  |
| --- | --- |
| ALG: Anti-lymphocyte globulin | **□** |
| ASA: Acetic salicylic acid | **□** |
| ATG: Anti-thymocyte globulin | **□** |
| AZA: Azathioprin | **□** |
| AZM: Azitromycin | **□** |
| BAS: Basiliximab | **□** |
| BLI: Blinded drug | **□** |
| CB: calcium channel blocker | **□** |
| CSA: Cyclosporin-A | **□** |
| DAC: Daclizumab | **□** |
| EVE: Everolimus | **□** |
| FK: Tacrolimus | **□** |
| FOT: Fotopheres | **□** |
| GAM: Gammaglobolin | **□** |
| GLU: Glucocorticosteroids | **□** |
| IL2: IL-2 block | **□** |
| MFA: Mycophenolate acid | **□** |
| MMF: Mycomophetil | **□** |
| NON: None | **□** |
| OKT: Anti-CD3 antibodies | **□** |
| OTH: Other | **□** |
| PLA: Plasmapheres | **□** |
| RAP: Rapamycin | **□** |
| SIR: Sirolimus | **□** |
| STA: Statins | **□** |
| TLI:TLI | **□** |

***Change in Immunosuppression?***

|  |  |  |
| --- | --- | --- |
| Reason for change | \_\_\_\_\_\_\_\_\_\_\_ | (1: acute rejection/ 2: chronic rejection/3: intolerances/ 4: chronic renal failure/ 5: treated diabetes/ 6: treated AHT/ 7: treated hyperlipidemia/ 8: neurological complication/ 9: infection/ 10: recurrence of initial disease/ 11: viral hepatitis/ 12: de novo cancer/ 13: recurrence cancer/ 14: autoimmune hepatitis/ 15: others) |
| Date of change |  |  |

**FORM C** **FOLLOW-UP cont.**

**Events (since last control)**

|  |  |  |
| --- | --- | --- |
| Acute rejections | \_\_\_\_\_\_\_\_\_\_\_ | (N: No/ ND: Unknown/Y: Yes) |
| No of acute rejections | \_\_\_\_\_\_\_\_\_\_\_ |  |
| Recurrent disease | \_\_\_\_\_\_\_\_\_\_\_ | (N: No/ ND: Unknown/Y: Yes) |
| Portal vein thrombosis (total) | \_\_\_\_\_\_\_\_\_\_\_ | (DND: Doppler not done/ N: No/ ND: Unknown/Y: Yes) |
| A. hepatica thrombosis (total) | \_\_\_\_\_\_\_\_\_\_\_ | (DND: Doppler not done/ N: No/ ND: Unknown/Y: Yes) |
| Biliary strictures (treated) | \_\_\_\_\_\_\_\_\_\_\_ | (N: No/ ND: Unknown/Y: Yes) |
| Liver tumor | \_\_\_\_\_\_\_\_\_\_\_ | (N: No/ ND: Unknown/Y: Yes) |
| Liver tumor comments | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | |
| Extrahepatic malignancy | \_\_\_\_\_\_\_\_\_\_\_ | (N: No/ ND: Unknown/Y: Yes) |
| Extrahepatic malignancy comments | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | |
| New onset diabetes (insulin) | \_\_\_\_\_\_\_\_\_\_\_ | (N: No/ ND: Unknown/Y: Yes) |
| New onset renal failure | \_\_\_\_\_\_\_\_\_\_\_ | (N: No/ ND: Unknown/Y: Yes) |
| Treatment renal failure | \_\_\_\_\_\_\_\_\_\_\_ | (DIA: Dialysis/ MTO: Medical treatment/ TX: Transplantation) |
| Children (numbers) | \_\_\_\_\_\_\_\_\_\_\_ |  |

**FORM D** **DEAD**

|  |  |  |  |
| --- | --- | --- | --- |
| Scandia number: | ­\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | Person number: | ­\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
|  |  |  |  |
| Surname: | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | First name: | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| Date of death | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |  |  |
|  |  |  |  |

**Death causes (see lists)**

|  |  |
| --- | --- |
| Primary death cause | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| Secondary death cause | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
|  | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
|  | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |

**List of diagnosis codes for first transplantation (Form A):**



**List of diagnosis codes for first transplantation (Form A) – continued:**

Et billede, der indeholder tekst, Parallel, sort-hvid, skærmbillede

Automatisk genereret beskrivelse**List of codes for death (Form D) or re-transplantation diagnosis (Form A):**

